Strategic Partnerships Acumen is advancing Aβ oligomer–targeting antibodies and a brain-delivery approach for Alzheimer’s, with ongoing clinical development. This creates opportunities for co-development, licensing, or manufacturing partnerships with pharma, CROs/CDMOs, and biotech focused on CNS programs.

Brain Delivery Partnerships Leverage Acumen's Enhanced Brain Delivery platform to explore collaborations with CNS delivery specialists, formulation developers, or carrier providers to accelerate scalable manufacturing, PK/PD work, and regulatory strategy for brain-penetrant antibody programs.

Clinical Development Support As a clinical-stage company with visible investor engagement, Acumen can benefit from CRO/CDMO services across early development, including antibody characterization, biomarker assay development for Aβ oligomers, GLP toxicology, and phased trial execution.

Cloud and Analytics With a cloud-first tech stack anchored by Microsoft Azure, Acumen is well positioned to engage data management, biostatistics, and regulatory-compliant trial analytics providers. Partners offering LIMS, eTMF, data integration, and AI-enabled insights can streamline trials and submissions.

Investor Engagement Acumen’s active fundraising and Boston-area presence present opportunities for strategic partnerships and licensing discussions with pharma. Support for deal sourcing, investor communications, and market intelligence could accelerate collaboration and value realization.